Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol

Marta Torres, Mar Bardagí, Xavier Roura, Giordana Zanna, Iván Ravera, Lluís Ferrer

Research output: Contribution to journalArticleResearchpeer-review

49 Citations (Scopus)

Abstract

Twenty-three dogs with a diagnosis of leishmaniosis (clinical stage II) were treated with meglumine antimoniate and allopurinol and were followed up for 2-9. years. The treatment showed efficacy and the clinical condition of the dogs improved markedly in the first 3. months of treatment. Anti-Leishmania antibody titres declined slowly although most dogs remained seropositive 1. year after beginning treatment. Inter-individual variability in the evolution of the titres was very high.The dogs presented with three types of complications during the follow-up period. (1) Three dogs experienced relapses characterized by clinical signs, high anti-Leishmania titres and high parasitaemia. (2) Eight dogs presented immune-mediated lesions, such as uveitis, arthritis and cutaneous vasculitis; in all of these cases, the dogs had high titres of anti-Leishmania antibodies at diagnosis and during follow-up. (3) Three dogs presented xanthine urolithiasis most likely due to the allopurinol treatment. In one case the xanthine uroliths led to hydronephrosis and nephrectomy. The study demonstrated a long survival for dogs with leishmaniosis treated with the combination of meglumine antimoniate and allopurinol. Clinicians should pay special attention to the appearance of immune-mediated lesions, especially in dogs with sustained high antibody titres, and to urolithiasis. © 2010 Elsevier Ltd.
Original languageEnglish
Pages (from-to)346-351
JournalVeterinary Journal
Volume188
Issue number3
DOIs
Publication statusPublished - 1 Jun 2011

Keywords

  • Allopurinol
  • Canine
  • Follow-up
  • Leishmaniosis
  • Meglumine antimoniate

Fingerprint Dive into the research topics of 'Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol'. Together they form a unique fingerprint.

Cite this